部分乳腺多形性腺瘤与唾液腺同类肿瘤共享PLAG1重排
该研究分析7例乳腺多形性腺瘤(含2例癌在多形性腺瘤中),采用FISH和RNA测序检测PLAG1与HMGA2重排。2例(28.6%)检出PLAG1重排,未发现HMGA2重排,并鉴定出新型TRPS1-PLAG1融合;随访6-158个月无复发或转移。
要点
- 乳腺多形性腺瘤罕见,但需纳入乳腺病理鉴别诊断,且有恶变为癌在多形性腺瘤中的潜能。
- 部分乳腺多形性腺瘤存在PLAG1重排,本研究检出率为28.6%(2/7)。
- 本研究报道新型TRPS1-PLAG1融合基因,未发现HMGA2重排。
核心结论
- 乳腺多形性腺瘤罕见但重要,可发生癌变,部分病例存在PLAG1重排并与唾液腺同类肿瘤共享分子改变。
- 本研究在乳腺多形性腺瘤中报道了新型TRPS1-PLAG1融合基因。
研究设计与样本
- 对7例乳腺多形性腺瘤(含2例癌在多形性腺瘤中)进行 clinicopathological 分析与分子检测。
- 采用FISH检测PLAG1重排,RNA测序检测HMGA2重排,RT-PCR和Sanger测序验证RNA测序结果。
主要发现
- 7例均发生于女性,组织学类似唾液腺同类肿瘤,呈双相上皮-肌上皮成分,免疫组化ER、PR、HER2均阴性。
- 2例癌在多形性腺瘤中,1例为微小浸润,1例为广泛浸润。
- PLAG1重排在2例(28.6%)中检出,未发现HMGA2重排。
- 1例中鉴定出新型TRPS1-PLAG1融合产物。
- 随访6-158个月,无患者出现复发或转移。
关键数值与推荐
- PLAG1重排检出率28.6%(2/7例乳腺多形性腺瘤)。
- 随访时间6-158个月,无复发或转移。
临床怎么用
- 乳腺多形性腺瘤应纳入乳腺肿瘤鉴别诊断,尤其需注意与伴有上皮-肌上皮成分且ER、PR、HER2阴性的病变区分。
- 对怀疑乳腺多形性腺瘤的病例,可考虑检测PLAG1重排辅助诊断。
- 需警惕多形性腺瘤恶变为癌在多形性腺瘤中的可能。
局限性
- 样本量小(7例),PLAG1重排频率与临床意义的评估受限。
- 随访时间范围较宽(6-158个月),长期生物学行为仍需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Pleomorphic adenoma (PA) of the breast, and especially its malignant transformation, is extremely rare and represents a diagnostic pitfall. Molecular alterations in this entity have not been investigated. We aimed to examine the clinicopathological features of our breast PAs and perform molecular analysis. METHODS AND RESULTS: Seven cases of breast PA, including two cases of carcinoma ex PA, were analysed. PLAG1 and HMGA2 gene rearrangements were assayed by fluorescence in-situ hybridisation (FISH) and RNA sequencing (RNA-Seq), respectively. Reverse transcription-polymerase chain reaction (RT-PCR) and Sanger sequencing were used to verify RNA sequencing results. All seven cases of breast PA occurred in women. The histological features were similar to the analogous tumour in salivary glands, including a dual epithelial-myoepithelial component and negativity of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) by immunohistochemistry. Of the two cases with carcinoma ex PA, one demonstrated minimal invasion and one was extensively invasive. PLAG1 rearrangements were identified in two cases (28.6%), but no rearrangements of HMG2A were found. A novel fusion product in PAs, TRPS1-PLAG1, was identified in one case. No patients had recurrence or metastasis with a follow-up period of 6-158 months. CONCLUSIONS: Breast PA is rare, but it is an important differential diagnosis of breast pathology with the potential to develop carcinoma ex PA. We report a novel TRPS1-PLAG1 fusion gene in breast PA.
引用
- Ma S, Zhao D, Liu Y, et al. Some pleomorphic adenomas of the breast share PLAG1 rearrangements with the analogous tumour of the salivary glands. Histopathology. 2021. PMID: 34292619. doi:10.1111/his.14461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。